Wednesday, 7 February 2018

Diabetic Peripheral Neuropathy — Pipeline Review, H1 2018


Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy Pipeline Review, H1 2018, provides an overview of the Diabetic Peripheral Neuropathy Metabolic Disorders pipeline landscape.
“Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain or discomfort in the feet or legsincluding prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes, smoking and kidney diseases. Treatment includes antidepressants, antiseizure and opioid analgesics.”
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy PipelineReview, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy Metabolic Disorders, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Peripheral Neuropathy Metabolic Disorders pipeline guide also reviews of key playersinvolved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 8, 2 and 8 respectively.
Diabetic Peripheral Neuropathy Metabolic Disorders pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy Metabolic Disorders.
The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy Metabolic Disorders by companies and universities/research institutes based on information derived from company and industryspecific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy Metabolic Disorders therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Diabetic Peripheral Neuropathy Metabolic Disorders therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy Metabolic Disorders

Table Of Content-
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Peripheral Neuropathy Overview
Diabetic Peripheral Neuropathy Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Diabetic Peripheral Neuropathy Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Peripheral Neuropathy Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Celgene Corp
Commence Bio Inc
Grunenthal GmbH
Immune Pharmaceuticals Inc
KPI Therapeutics Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Novaremed Ltd
Reata Pharmaceuticals Inc
Relief Therapeutics Holding AG
ViroMed Co Ltd
Diabetic Peripheral Neuropathy Drug Profiles
amitriptyline + ketamine hydrochloride Drug Profile
Product Description
Posted by at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)